Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/33039
Title: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2017
Citation: Ann. Oncol..2017 04;(28)4:761-768
Abstract: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies.
PMID: 28057664
URI: https://hdl.handle.net/20.500.12530/33039
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5834072.pdf284.58 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.